Richard E. Wilcox, Ph.D.

Richard Wilcox

James T. Doluisio Centennial Fellowship Professor Emeritus

AREAS OF EXPERTISE

Neuropharmacology / neurochemistry
Synaptic transmission / signal transduction
Parkinson’s disease
Schizophrenia
Major depressive disorder
Bipolar disorder
Alzheimer’s disease
Epilepsy
Attention deficit hyperactivity disorder
Anxiety

  1. Brusniak, M. Y., R. S. Pearlman, et al. (1996). “Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.” Journal of Medicinal Chemistry 39(4): 850-9.
  2. Mak, C. K., M. Avalos, et al. (1996). “Improved models for pharmacological null experiments: calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines.” Neuropharmacology 35(5): 549-70.
  3. Erickson, C. K., R. E. Wilcox, et al. (1998). “Education of nonscientists about new alcohol research: results of two types of presentations plus 6-month follow-up.” Alcoholism: Clinical & Experimental Research 22(9): 1890-7.
  4. Wilcox, R. and B. McMillen (1998). “The rational use of drugs as therapeutic agents for the treatment of the alcoholisms.” Alcohol. 15(2): 161-77.
  5. Wilcox, R., T. Tseng, et al. (1998). “CoMFA-based prediction of agonist affinities at recombinant D1 vs. D2 dopamine receptors.” J. Med. Chem. 41: 4385-4399.
  6. Wilcox, R. E., R. A. Gonzales, et al. (1998). Introduction to neurotransmitters, receptors, signal transduction and second messengers. Textbook of Psychopharmacology. C. B. Nemeroff and A. F. Schatzberg, American Psychiatric Press: 3-36.
  7. Avalos, M. A., C. Mak, et al. (2000). “Non-linear analysis of partial dopamine agonist effects on camp in c6 glioma cells.” J. Pharm. Tox. Meth. 45: 17-37.
  8. Edwards, S., S. L. Hoyler, et al. (2000). “Beta2-adrenoreceptor inverse agonists enhance cAMP accumulation via up-regulation of functional receptor density at the cell surface.” Soc. Neuroscience Abstr 26: 116 (45.14).
  9. Galindo, D., S. Edwards, et al. (2000). “Comparative effects of a full D1 agonist, a D2 receptor agonist, and ethanol on the phosphorylation of DARPP-32 and the NR1 subunit of the NMDA receptor.” Society for Neuroscience Abstracts 30: 786 (#290.6).
  10. Raofi, S., P. K. Wong, et al. (2000). “Modulation of G-protein linked cAMP accumulation in immortalized murine cortical astrocytes by retroviral infection.” Brain Research 862(1-2): 230-3.
  11. Wilcox, R. E. (2000). Dopamine. Encyclopedia of Psychology and Neuroscience, 3rd edition. W. E. Craighead and C. B. Nemeroff. New York, John Wiley. 1: 454-457.
  12. Wilcox, R. E. and C. K. Erickson (2000). “Commentary – Neurobiological aspects of the addictions.” J. Addictions Nursing, 12(3/4), 117-133 12(3/4): 117-133.
  13. Wilcox, R. E., W.-H. Huang, et al. (2000). “CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.” Journal of Medicinal Chemistry 43(16): 3005-3019.
  14. Wilcox, R. E., J. E. Ragan, et al. (2000). “High-affinity agonist interactions at recombinant 5HT7 receptors – estimates using CoMFA (comparative molecular field analysis).” Soc. Neuroscience Abstr. 26: 2157 (810.9).
  15. Chu, J., W. Wilczynski, et al. (2001). ” Pharmacological Characterization of the D1 and D2-like Dopamine Receptors from the Brain of the Leopard Frog, Rana pipiens.” Brain Behavior and Evolution 57: 328-342.
  16. Doherty, J. M. and R. E. Wilcox (2001). “Acute in vivo dopaminergic drug effects on striatal versus nucleus accumbens protein phosphorylation.” Bain Research: in progress.
  17. Erickson, C. K. and R. E. Wilcox (2001). “Pharmacology of addiction.” Tex. Pharm. Assoc. J. winter: 8-13.
  18. Erickson, C. K. and R. E. Wilcox (2001). “Neurobiological causes of addictions.” J. Social Work Practice in the Addictions 1(3): 7-22.
  19. Wilcox, R. E. and C. K. Erickson (2001). Brain biology of drug abuse and addiction. Neurobiology of Addictions – Implications for Clinical Practice. R. T. Spence, D. M. DiNitto and S. L. A. Straussner. Binghamton, NY, Haworth Press, Inc.: 7-23.
  20. Wilcox, R. E., J. E. Ragan, et al. (2001). “High-affinity interactions of ligands at recombinant guinea pig 5HT7 receptors.” J. Computer-Aided Molecular Design 15: 883-909.
  21. Edwards, S., S. L. Hoyler, et al. (2002). “Sensitization of beta2-adrenoreceptor-mediated cAMP generation after chronic exposure to inverse agonists.” British J. Pharmacology: in preparation.
  22. Edwards, S., D. Simmons, et al. (2002). “Antagonistic Effects of Dopaminergic Signaling and Ethanol on PKA-Mediated Phosphorylation of DARPP-32 and the NR1 Subunit of the NMDA Receptor.” Alcoholism: Clinical and Experimental Research 26(2): 173-180.
  23. Huang, W.-H., R. E. Wilcox, et al. (2002). “Comparative Molecular Field Analysis (CoMFA) for sulfoxidation reactions in Mortierella isabellina ATCC 42613 and Helminthosporim sp. NRRL 4671.” J. Molecular Modeling 8: 8-23.
  24. Scott, A., J. Doherty, et al. (2002). “Oxotremorine-M, oxotremorine-S, and eticlopride/naltrexone, but not fluoxetine, enhance striatal phosphorylation of the NMDA-R1 receptor subunit in mice following acute in vivo challenge.” Brain Research: in preparation.
  25. Trzeciakowskii, J. P. and R. E. Wilcox (2002). “Estimating the relative efficacy of partial dopamine receptor agonists in recombinant receptor expression systems: Comparison of functional interaction and combined effects models.” J. Thoretical Biol.: submitted.
  26. Doddakashi, V., L. Hauser, et al. (2003). “Female suicide in Texas 1994 -1998.” Texas Medicine: in press.
  27. Erickson, C. K., R. E. Wilcox, et al. (2003). “Effectiveness of Addiction Science Presentations to Treatment Professionals, Using a Modified Solomon Study Design.” Journal of Drug Education in press.
  28. Lawson, K. A., R. E. Wilcox, et al. (2003). “Educating Professionals to Promote Addiction Science Research: Demographics of Knowledge and Belief Changes.” Substance Abuse and Misuse 2003.
  29. Li, S., D. Simmons, et al. (2003). “Acute in vivo challenge with the antidepressant fluoxetine enhances expression of striatal pDARPP-32, an effect that is reversed by ethanol.” J. Neural Trans.: in preparation.
  30. Wilcox, R. E. and C. K. Erickson (2003). “Prevention of relapse to addiction – information for the practitioner.” Texas Medicine submitted.
Contact Information
Phone:
512-471-5199
Campus location:
PHR 5.224B

US Mail Address:
The University of Texas at Austin
PHR 5.224B
2409 University Ave., A1915
Austin, TX 78712

FEDEX Address:
107 W. Dean Keeton St.
PHR 5.224B
The University of Texas at Austin
Austin, TX 78712